Glaukos Co. (NYSE:GKOS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $163.25.

Several research analysts recently commented on GKOS shares. UBS Group began coverage on Glaukos in a research report on Friday, December 6th. They set a "buy" rating and a $182.00 price target for the company. BTIG Research raised their target price on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Mizuho raised shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Piper Sandler reissued an "overweight" rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Needham & Company LLC boosted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st.

Glaukos Stock Up 5.5 %

NYSE:GKOS traded up $5.34 during trading hours on Monday, reaching $103.13. 1,403,487 shares of the stock were exchanged, compared to its average volume of 855,302. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos has a twelve month low of $84.08 and a twelve month high of $163.71. The stock has a market cap of $5.83 billion, a PE ratio of -35.93 and a beta of 0.99. The firm has a 50 day moving average of $143.84 and a 200 day moving average of $138.41.

Remove Ads

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, equities analysts expect that Glaukos will post -1.08 earnings per share for the current year.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,744 shares of company stock worth $2,504,131 in the last ninety days. 6.40% of the stock is owned by company insiders.

Institutional Trading of Glaukos

A number of institutional investors have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Glaukos in the 4th quarter valued at $12,367,000. Forum Financial Management LP acquired a new position in Glaukos during the fourth quarter worth about $211,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Glaukos by 20.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 162,326 shares of the medical instruments supplier's stock worth $24,339,000 after acquiring an additional 27,889 shares in the last quarter. State of Wyoming lifted its holdings in shares of Glaukos by 2.3% in the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after acquiring an additional 72 shares during the last quarter. Finally, Thornburg Investment Management Inc. boosted its stake in shares of Glaukos by 18.4% in the 4th quarter. Thornburg Investment Management Inc. now owns 45,583 shares of the medical instruments supplier's stock valued at $6,835,000 after purchasing an additional 7,072 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.